Transcode Therapeutics (RNAZ) Total Current Liabilities (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Total Current Liabilities for 7 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 244.97% year-over-year to $5.4 million; the trailing twelve-month figure through Jun 2026 stood at $5.4 million (up 244.97% YoY), and the FY2025 full-year result was $3.5 million, up 26.06% from the prior year.
• Total Current Liabilities steadied at $5.4 million in Q2 2026 per RNAZ's latest filing, from $5.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $5.6 million in Q3 2023 and bottomed at $1.6 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $3.5 million across 5 years, with a median of $3.5 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Total Current Liabilities plunged 59.2% in 2024, then soared 244.97% in 2026.
• Over 5 years, Total Current Liabilities stood at $4.3 million in 2022, then fell by 19.71% to $3.5 million in 2023, then slipped by 20.59% to $2.8 million in 2024, then climbed by 26.06% to $3.5 million in 2025, then surged by 54.5% to $5.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $5.4 million, $5.4 million, and $3.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.